Vistagen appoints Cindy Anderson as CFO; Jerrold Dotson retires after decade-long tenure

Vistagen Therapeutics, Inc.

Cindy Anderson appointed CFO effective August 21, 2023, succeeding Jerrold Dotson upon his planned retirement.
Anderson brings 15+ years biopharma experience, most recently Chief Accounting Officer at Alnylam Pharmaceuticals (ALNY).
She previously held senior finance roles at Alexion Pharmaceuticals and began her career at PwC and EY.
No arrangements or related-party transactions exist in connection with Anderson's appointment.
CEO Shawn Singh expressed gratitude for Dotson's decade of service and welcomed Anderson's financial expertise.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Cynthia Anderson

Chief Financial Officer

VTGN · Vistagen Therapeutics, Inc.

Effective: 2023-08-21
Filed: August 22, 2023, 7:59 PM ET

announced the appointment of Ms. Cynthia Anderson, C.P.A., as the Company’s Chief Financial Officer

Departed

Jerrold Dotson

Chief Financial Officer

VTGN · Vistagen Therapeutics, Inc.

Effective: 2023-08-21
Successor: Cynthia Anderson
Filed: August 22, 2023, 7:59 PM ET

Ms. Anderson replaces Mr. Jerrold Dotson upon his retirement, effective August 21, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Cynthia Anderson was appointed as Chief Financial Officer at Vistagen Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

announced the appointment of Ms. Cynthia Anderson, C.P.A., as the Company’s Chief Financial Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Jerrold Dotson retired as Chief Financial Officer at Vistagen Therapeutics, Inc..

Action: retired
Role: Chief Financial Officer

Exact text from the filing

Ms. Anderson replaces Mr. Jerrold Dotson upon his retirement, effective August 21, 2023

View on SEC.gov

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-024370

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.